FTC Unanimously Agrees to Keep Close Eye on PBMs, Higher Drug Costs

The U.S. Federal Trade Commission unanimously agreed to keep a closer eye on the role pharmacy benefits managers (PBMs) play in pricing prescription drugs. The vote came a little over one week after the FTC announced it would probe claims regarding the role the middlemen play in determining retail prices of prescription drugs.